Most Read Articles
Stephen Padilla, 24 Jan 2020
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.

PyloBalance as an adjunct therapy in the treatment of H. pylori infections

17 Jul 2019
All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 24 Jan 2020
Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.